Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LCR Regenerans
- Development stage
- Phase 3
- Lead developer
- Probionov
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Vaginal, Oral
01
Overview
LCR Regenerans is a proprietary, total freeze-dried culture of the probiotic strain *Lacticaseibacillus rhamnosus* Lcr35 (previously known as *Lactobacillus rhamnosus* Lcr35). [14, 24] It is a live biotherapeutic product designed to restore and maintain a healthy microbial balance in the body, particularly in the vaginal and gastrointestinal tracts. [17] The mechanism of action involves colonization, production of lactic acid to lower the pH, formation of a protective biofilm that inhibits pathogenic organisms like *Candida albicans* and *Gardnerella vaginalis*, and modulation of the host's innate immune response. [6, 13, 24] It is marketed as a medical device for regenerating the vaginal flora and is also being developed as a pharmaceutical for preventing recurrent vulvovaginal candidiasis, bacterial vaginosis, and other conditions. [14]
- Brand names
- Lcr RestituoGynophilusBacilor
- Other names
- Total freeze-dried culture of Lactobacillus rhamnosus Lcr35
02
Targets
FOXO1 (Forkhead box protein O1)
Beyond the preview
Go deeper on LCR Regenerans.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LCR Regenerans.